Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics comparison of ovarian cancer cells with drug administration and tRNA transfection (24 hours)

ABSTRACT: Quantitative proteome analyses of ovarian cancer cells (TOV-112D cells) in the following three conditions were carried out. 1: Treatment with transfection reagent followed by treatment with DMSO 2: Treatment with transfection reagent followed by treatment with 100nM Camptothecin 3: Treatment with transfection reagent and 10nM tRNALeu(TAA) followed by treatment with 100nM Camptothecin

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Takeshi Masuda

PROVIDER: PXD066104 | JPOST Repository | Sat Jul 26 00:00:00 BST 2025

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	240818_CPTLeu_1.mzML	Mzml
	240818_CPTLeu_1.raw	Raw
	240818_CPTLeu_2.mzML	Mzml
	240818_CPTLeu_2.raw	Raw
	240818_CPTLeu_3.mzML	Mzml

Items per page:

1 - 5 of 20

Similar Datasets

Proteomics comparison of ovarian cancer cells with drug administration and tRNA transfection

Project description:Quantitative proteome analyses of ovarian cancer cells (TOV-112D cells) in the following three conditions were carried out. 1: Treatment with transfection reagent for 4 hours followed by treatment with DMSO 2: Treatment with transfection reagent for 4 hours followed by treatment with 100nM Camptothecin 3: Treatment with transfection reagent and 10nM tRNALeu(TAA) for 4 hours followed by treatment with 100nM Camptothecin

2025-05-22 | PXD052458 | JPOST Repository

The drug-elicitable alternative splicing module for tunable vector expression in the heart

Project description:RNA Seq datasets from WT or AAV-injected mice treated with 10 mg/kg risdiplam or solvent. RNA Seq datasets from plasmid-transfection HEK293T cells treated with 1uM risdiplam or DMSO.

2025-04-13 | GSE270445 | GEO

Expression data HEK293T cells transfected with either Ago2, Ago2 + miR-1, Ago2 + miR-124, mock

Project description:HEK293T cell expression data from four conditions: mock transfection, Ago2 transfection, Ago2 & miR-1 transfection, and Ago2 & miR-124 transfection. RNA was isolated directly from 10cm dishes using Trizol reagent and amplified. Set of arrays that are part of repeated experiments Compound Based Treatment: FLAG-Ago2 transfection Keywords: Biological Replicate

2008-04-08 | GSE11080 | GEO

High-resolution transciptome mapping and N6-methyladenosine modification mapping of 3T3-L1 derived adipocytes

Project description:Purpose:Detect transcriptome-wide mapping of m6A modifications by MeRIP-seq between Rhein and DMSO treated 3T3-L1 differentiation adipocytes at the preadipocytes, MCE stage and differentiation stage. Methods:Total RNA was extracted using TRIzol Reagent followed by chemical fragmentation. The fragmented RNA was incubated with anti-m6A antibody. The desired m6A-enriched RNA eluate was used to construct cDNA library in parallel with input control. Conclusion: Our study revealed the difference of m6A-methylated RNA between DMSO and Rhein treated cells by RNA-seq and MeRIP-seq technologies.

2021-06-01 | GSE173702 | GEO

High-resolution transcriptome mapping and N6-methyladenosine modification mapping of 3T3-L1 derived adipocytes (RNA-Seq)

2021-06-01 | GSE171785 | GEO

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Project description:PRMT5 Co-IP mass spectrometry: Lysates of MCF-7 RB1-knockout cells were pulled down with a PRMT5 antibody or IgG control. The pulldowns were subjected to mass spectrometry analysis. QEX2_981005, QEX2_981006, QEX2_981007: DMSO, IgG QEX2_981008, QEX2_981009, QEX2_981010: DMSO, PRMT5 antibody QEX2_981011, QEX2_981012, QEX2_981013, GSK, IgG QEX2_981014, QEX2_981015, QEX2_981016, GSK, PRMT5 antibody SDMA PTM analysis: MCF-7 RB1-knockout cells were transfected with a PRMT5 siRNA or a control siRNA. Lysates were collected three days after transfection and subjected to mass spectrometry analysis. LUM1_1000791, LUM1_1000792, LUM1_1000793: control SiRNA LUM1_1000794, LUM1_1000795, LUM1_1000796: PRMT5 siRNA [

2024-01-12 | PXD046996 | Pride

Therapeutic modulation of nemo-like kinase in primary and acquired endocrine-resistant breast cancer

Project description:Purpose: To assess if NLK modulates ER target gene expression, we performed transcriptome sequencing following NLK inhibition or tamoxifen treatment in the BT483 or T47D-TamR cells under estrogen-deprived condition. Methods: BT483 and T47D-TamR cells were treated with NLK-specific siRNAs, or VX-702, or Tamoxifen under estrogen-deprived condition to examine the expression profile changes of ER target genes. NovaSeq 6000 S2 Reagent Kit (Illumina) was used for paired-end reads (2×150 bp) sequencing reactions. The expression changes of ER target genes following NLK inhibition are compared to their changes following tamoxifen treatment. Results: Our results show that the ER target gene expression changes following NLK silencing or VX-702 treatment correlate with their expression changes following tamoxifen treatment.

2021-01-11 | GSE141696 | GEO

Drug treatment comparison

Project description:H460 cells were treated with 5-FU, cytarabin, cisplatin, paclitaxel, and cytochalasin D. Gene expression changes induced by drug treatment were compared. Keywords: other

2005-01-27 | GSE2182 | GEO

Transcriptional changes in glioma cells following treatment with 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125), Tunicamycin, and 0.1% DMSO (in media)

Project description:Purpose: Evaluate transcriptional changes in glioma derived stem cells, U251, and normal human astrocytes following treatment with NH125, Tunicamycin, or 0.1% DMSO Methods: Glioma derived stem cells, U251 and Normal Human Astrocytes were plated in individual dishes and treated with either 2.5 micromolar NH125, 1.0 mcg/mL Tunicamycin, or 0.1% DMSO (vehicle) for twenty-four hours followed by total RNA extraction, library preparation and next generation sequencing Results: Using our analysis pipeline we mapped our sequence reads to the reference genome GRCh38. Following read count normalization and differential expression of NH125 and tunicamycin treated samples to vehicle treated controls we found that NH125 and tunicamycin treatment lead to activation of similar signalling pathways Conclusions: We present an optimized workflow for analysis of transcriptional changes in drug treated glioma derived stem cells, glioblastoma cells and normal human astrocytes

2018-03-02 | GSE102505 | GEO

Drug treatment comparison

Project description:H460 cells were treated with 5-FU, cytarabin, cisplatin, paclitaxel, and cytochalasin D. Gene expression changes induced by drug treatment were compared.

2010-06-10 | E-GEOD-2182 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data